The anti-BAFF monoclonal antibody belimumab is still the sole targeted therapy licensed for SLE, lending credence to the widely accepted notion that B cells play central roles in lupus pathogenesis. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.